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Abstract Tumor necrosis factor-K (TNF-K) is a proinflamma-
tory cytokine that is involved in the pathogenesis of several
human CNS disorders. The AU-rich element (ARE) in the 3P-
untranslated region (UTR) of TNF-K mRNA is implicated in
post-transcriptional control of TNF-K. In this study, we showed
that a human neuronal ELAV-like protein binds to the ARE in
the 3P-UTR of TNF-K mRNA. The protein binds to the uridine
stretch in AUUUA pentanucleotides inside the ARE in the 3P-
UTR of TNF-K mRNA. The TNF-K mRNA-binding region in
the protein appears to be identical to the c-myc and IL-3 mRNA-
binding regions. Moreover, this study showed that in vitro
treatment of neuroblastoma cells with interleukin-4 (IL-4), which
inhibits TNF-K production, reduced the expression of the
neuronal ELAV-like proteins. These results suggest that the
expression of neuronal ELAV-like proteins may be closely
associated with the expression of TNF-K in neuronal cells.
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1. Introduction
Tumor necrosis factor-alpha (TNF-K) is one of the key
proin£ammatory cytokines, which mediate many in£amma-
tory processes. It has been implicated in the pathogenesis of
several human central nervous system (CNS) disorders includ-
ing multiple sclerosis [1,2], AIDS dementia [3,4], and cerebral
malaria [5]. TNF-K is critically important in the early events
leading to the initiation of experimental autoimmune encepha-
lomyelitis. It damages oligodendrocytes and myelin, and in-
duces apoptosis in neuronal cells via a pathway that involves
the formation of reactive oxygen intermediates. Furthermore,
TNF-K may also be a neurotoxin induced by human immu-
node¢ciency virus type 1. Therefore, TNF-K appears to play a
variety of signi¢cant roles in pathophysiological conditions of
the CNS.
The production of TNF-K has been demonstrated in the
CNS. Although microglial and astroglial cells mainly produce
the TNF-K in the CNS [6], evidence has been presented that
neurons synthesize TNF-K de novo [7^10]. Immunohisto-
chemical studies identi¢ed TNF-K-like immunoreactive neu-
rons in the hypothalamus, the bed nucleus of the stria termi-
nalis, the caudal raphe nuclei, and along the ventral pontine
and medullary surfaces [9]. In response to the systemic admin-
istration of lipopolysaccharide (LPS), TNF-K mRNA ap-
peared in a cascade of neurons in the pericircumventricular
nuclei [10]. Treating mature human primary neurons with
soluble HTLV-1 Tax1 induced the TNF-K gene in the neurons
[7]. TNF-K mRNA has also been detected in neuroblastoma
cell lines, and stimulation with LPS/beta/gamma-interferon
(IFN-Q) can induce TNF-K in neuroblastoma cells [11]. There-
fore, neurons and neuron-derived cells are thought to produce
TNF-K.
In many cells, post-transcriptional regulation plays a major
role in the expression of TNF-K. The 3P-untranslated region
(UTR) of TNF-K mRNA contains sequences that suppress
the translation of TNF-K, and sequences in the 3P-UTR con-
fer translational control of TNF-K expression. The AU-rich
element (ARE) located in the 3P-UTR includes a major class
of cis-elements that regulate the translation of TNF-K. This
regulatory process involves the binding of cytoplasmic and
nuclear RNA-binding proteins to a region or regions of
mRNA, thereby increasing the stability of the mRNA. Iden-
tifying the proteins that bind to TNF-K mRNA is an impor-
tant step in clarifying the mechanisms of post-transcriptional
control of TNF-K expression, and much e¡ort has already
been devoted to identifying these proteins. In this study, we
showed that a neuronal protein could bind to the ARE of
TNF-K mRNA.
2. Materials and methods
2.1. Cell extracts
Human brain cell extract was prepared from the hippocampus of a
brain, removed at autopsy from a male patient who died from a non-
neurological disease. Brain sections were homogenized in phosphate
bu¡ered saline (PBS) and washed three times in PBS. After centrifu-
gation, the pellet was resuspended in a cytosolic extract bu¡er (10 mM
HEPES, pH 7.5, 40 mM KCl, 3 mM MgCl2, 2 mM DTT, 5% glyc-
erol, 0.5% NP-40 and proteinase inhibitors), and incubated on ice for
30 min. The nuclei were removed by two 5-min centrifugations at
5000Ug. The supernatant was used as the cell extract. Neuroblastoma
cell extract was prepared in the same manner from 106 neuroblastoma
line IMR-32 cells.
2.2. Synthetic ribonucleotides
Poly(U) and poly(A) synthetic ribonucleotide homopolymers were
purchased from Pharmacia. The oligoribonucleotides that correspond
to the ARE in the 3P-UTR of TNF-K (CACUUAUUAUUUAUUA-
UUUAUUU-AUUAUUU) and c-myc (UAACAGAUUUGUAUU-
UAAGAAUU-GUUUUUA) mRNA were synthesized, and their pu-
rity was con¢rmed by high-pressure liquid chromatography.
2.3. Electrophoretic mobility gel-shift assay
Two Wg of brain cell or neuroblastoma cell extract or the indicated
amount of HuC/ple21 recombinant protein [12] were incubated with
40 000 cpm radiolabeled RNA in a ¢nal volume of 20 Wl in binding
bu¡er (10 mM Tris-HCl, pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.5%
Triton X-100, 1 mM dithiothreitol, 10% glycerol, 250 Wg/ml yeast
tRNA, 0.5 mg/ml bovine serum albumin) in the presence or absence
of total IgG containing ANNA-1/anti-Hu antibodies or IgG from a
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healthy individual at 37‡C for 10 min. After incubation, the reactions
were resolved on a 6% polyacrylamide-0.5UTBE gel containing 10%
glycerol. Subsequently, the gels were dried with heat under vacuum,
and exposed to X-ray ¢lm for autoradiography for 2 h at 380‡C. For
competitive analyses, homopolymers or c-myc oligoribonucleotide
were added to the reaction and resolved.
2.4. RNA UV cross-linking assays
Fifteen Wg of brain cell or neuroblastoma cell extract was incubated
with 40 000 cpm radiolabeled RNA in a ¢nal volume of 20 Wl in
binding bu¡er at 37‡C for 10 min. The reactions were exposed to
0.12 J/cm2 in a UV cross-linker, and were separated on 13% sodium
dodecyl sulfate polyacrylamide gels (SDS-PAGE). The gels were dried
and exposed to X-ray ¢lm.
2.5. Quantifying binding a⁄nity
The binding a⁄nity of TNF-K mRNA-HuC/ple21 complex was
quanti¢ed using the gel electrophoresis techniques of Fried and
Crothers [13]. HuC/ple21 was incubated with 32P-labeled TNF-K
mRNA for 10 min at 37‡C in binding bu¡er. Increasing concentra-
tions of 32P-labeled TNF-K mRNA and constant concentrations of
unlabeled TNF-K mRNA (1.5 WM) and the protein (2 Wg) were added
to the reactions. The bound RNA was separated from unbound RNA
using the gel-shift assay. The dried gels were scanned and the results
quanti¢ed using a phosphor screen image analyzer. The data were
plotted according to the ¢rst-order rate equation given in Riggs et
al. [14], and the apparent dissociation constant (Kd) was calculated by
linear regression.
2.6. Treatment of neuroblastoma cells with cytokines
IMR-32 neuroblastoma cells (2U105/ml) were incubated with INF-
Q (10 ng/ml) and LPS (1 Wg/ml) for 2 h, or with IL-4 (10 ng/ml) for 2 h
or the time indicated. After incubation, the cells were harvested and
cell extracts were isolated. These cell extracts were separated on 13%
SDS-PAGE. Proteins were transferred to nitrocellulose in a transfer
electrophoresis unit at 400 mA at 4‡C for 2 h. After the blots were
washed, they were reacted with 1:500 diluted ANNA-1/anti-Hu anti-
sera for 1 h, followed by a 2-h incubation with a 1:2000 dilution of
alkaline phosphatase-conjugated goat anti-human IgG. The blots
were developed with nitroblue tetrazolium chloride and 5-bromo-
4-chloro-3-indolylphosphate toluidine salt.
3. Results
3.1. Binding to the ARE of TNF-K of cell extracts from human
brain tissue and neuroblastoma line cells
The 3P-AU-rich sequence of human TNF-K mRNA has
previously been shown to play a major role in post-transcrip-
tional regulation. To determine the factors that are involved
in the post-transcriptional regulation of TNF-K mRNA in the
CNS, we examined the binding of neuronal cytosolic proteins
to the ARE in the 3P-UTR of TNF-K mRNA. Cytosolic ex-
tracts were prepared from human hippocampus tissue and
neuroblastoma cell line IMR-32, which is known to display
many features of both cholinergic and adrenergic neurons.
Previous studies by Hel et al. [15] revealed that one of the
protein-binding regions of TNF-K mRNA is positioned be-
tween nt 1291 and 1320 inside the ARE, and that this region
is crucial for both translational repression and LPS inducibil-
ity of TNF-K in monocytes and macrophages. Therefore, we
prepared a 30-mer TNF-K mRNA oligoribonucleotide (nt
1291 and 1320) and used it as a probe for further experiments.
UV cross-linking assays revealed that TNF-K mRNA
bound to cytosolic proteins in both the human hippocampal
tissue and neuroblastoma line cell extracts (Fig. 1a). A single
protein-RNA complex was detected in the neuroblastoma cell
extract with a relative molecular mass of 38 kDa, and two
complexes of approximately 34^42 kDa were detected in the
hippocampal tissue extract. Since the molecular weights of the
TNF-mRNA-binding proteins in the extracts were similar to
those of neuronal ELAV-like proteins, we examined the pos-
sibility that the TNF-K mRNA-binding proteins in neurons
might be neuronal ELAV-like proteins. Anti-neuronal nuclear
antibodies, which speci¢cally react with ELAV-like proteins,
were incubated with the extract and radiolabeled TNF-
mRNA in binding bu¡er, and resolved on non-denaturing
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Fig. 1. (a) UV cross-linking analysis of extracts (10 Wg) from IMR-32 neuroblastoma line cells and human hippocampus tissue with the radiola-
beled 30-mer within the AU-rich sequence in the 3P-UTR of TNF-K mRNA. (b, c) E¡ects of antibodies against human ELAV-like proteins
(ANNA-1/anti-Hu antibodies) on RNA binding of extracts from the human hippocampus tissue (b) and IMR-32 neuroblastoma line cells (c).
Control, IgG (0.5 mg/ml) from serum of a healthy individual; ANNA-1/anti-Hu; IgG (0.05 to 5 mg/ml in (b) and 0.5 mg/ml in (c)) from serum
of a patient with paraneoplastic neurologic syndromes; none, no IgG was added in the reaction of the extracts and a radiolabeled 30-mer with-
in the AU-rich sequence in the 3P-UTR of TNF-K mRNA.
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gels. In the gel-shift assay with the hippocampal tissue extract,
two protein-RNA complexes were detected (Fig. 1b). The ad-
dition of antibodies decreased the intensity of the autoradio-
graphic signals of the slower migrating complex in a dose-
dependent manner (0.05 to 5 mg/ml), while the addition of
control IgG (0.5 mg/ml) did not a¡ect the intensity. The in-
tensity of the faster migrating complex was unchanged by the
addition of antibodies. With cell extract of neuroblastoma cell
line IMR-32, a single protein-RNA complex was detected in
the gel-shift assay. The addition of antibodies (0.5 mg/ml)
reduced the intensity of the complex’s autoradiographic signal
(Fig. 1c). These results suggest that neuronal ELAV-like pro-
teins might bind to TNF-K mRNA.
3.2. The binding of neuronal ELAV-like proteins to TNF-K
mRNA
We then examined the binding of neuronal ELAV-like pro-
teins to TNF-K mRNA using a recombinant protein, HuC/
ple21, which we previously cloned from a human hippocam-
pal cDNA library [12], as the neuronal ELAV-like protein.
The gel-shift assay using the recombinant protein and TNF-
K mRNA revealed that this neuronal protein formed a com-
plex with TNF-mRNA (Fig. 2a). The gel-shift assay using
RNA recognition domain (RRM) deletion mutants indicated
that the ¢rst two tandem RRMs bound to the oligoribonu-
cleotide, but not the last two, as previously demonstrated with
mRNA for interleukin-3 (IL-3), c-myc, and c-fos (Fig. 2b).
Furthermore, a deletion in the ¢rst two RRM peptides
showed that HuC/ple21 amino acids 185^192 were important
for binding to TNF-K mRNA, as was observed in the binding
of the protein to mRNA for c-myc and IL-3 (Fig. 2c). Com-
petitive binding of HuC/ple21-TNF-K mRNA with poly(U)
and poly(A) homopolymers, and the 30-mer oligoribonucleo-
tide corresponding to the ARE in the 3P-UTR of c-myc
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Fig. 2. Binding of the HuC/ple21 recombinant protein (0.02 to 2.0 Wg/reaction) (a), two tandem RNA recognition motifs (RRM) of HuC/ple21
(0.2 Wg/ml) (b), and deletion mutants of HuC/ple21 RRM1+2 (c) to the 30-mer within AU-rich sequence in the 3P-UTR of TNF-K mRNA.
(3), no recombinant protein in the reaction. Slope in (a) indicates increasing concentrations of HuC/ple21. (d) Competitive analysis of binding
of HuC/ple21 to the 30-mer within ARE in the 3P-UTR of TNF-K mRNA by increasing concentrations (0.045 to 4.5 mM) of unlabeled
poly(U) and poly(A) ribohomopolymers, and unlabeled 30-mer within ARE in the 3P-UTR of c-myc mRNA. Slopes indicate increasing concen-
trations of each competitor.
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mRNA showed that the poly(U) homopolymer and c-myc
mRNA e⁄ciently competed with TNF-K mRNA to bind to
HuC/ple21, but the poly(A) homopolymer did not (Fig. 2d).
The binding plots indicated that TNF-K mRNA bound to
HuC/ple21 with a⁄nity in a saturable manner. A Scatchard
analysis showed that TNF-K mRNA bound to the neuronal
ELAV-like protein with an apparent dissociation constant
(Kd) of 10.8 nM (Fig. 3).
3.3. E¡ects of cytokines that regulate TNF-K on neuronal
ELAV-like proteins
It has been demonstrated that INF-Q and LPS stimulate
TNF-K production in monocytes, macrophages, and IMR-
32 neuroblastoma cells [11,16^18]. In contrast, IL-4 sup-
presses TNF-K production [19^22]. We investigated whether
these cytokines a¡ected the expression of neuronal ELAV-like
proteins in IMR-32 neuroblastoma cells. Immunoblot analysis
showed that treatment with INF-Q and LPS did not alter the
expression of ELAV-like proteins. On the other hand, the
expression of ELAV-like proteins decreased in the neuroblas-
toma cells treated with IL-4 for 2 h (Fig. 4a). Less ELAV-like
protein was induced with a longer treatment of IMR-32 cells
with IL-4 (Fig. 4b).
4. Discussion
In this study, we described that cytosolic proteins contained
in human hippocampal tissue and neuroblastoma line cell ex-
tract bind to a 30-mer oligoribonucleotide within the ARE in
the 3P-UTR of TNF-K mRNA, and that the proteins are
neuronal ELAV-like proteins. The production of cytokine is
regulated both at the transcriptional and post-transcriptional
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Fig. 3. (a) Binding curve of TNF-K mRNA to HuC/ple21. Recombinant HuC/ple21 protein and increasing concentrations of 32P-labeled TNF-
K mRNA were incubated for 10 min at 37‡C with excess amount of unlabeled TNF-K mRNA (1.5 WM). B, 32P-labeled TNF-K mRNA speci¢-
cally bound. (b) Scatchard analysis of the binding of TNF-K mRNA to HuC/ple21. Bound to free TNF-K mRNA (B/F) is plotted against
bound 32P-labeled TNF-K mRNA (B).
Fig. 4. (a) E¡ect of IL-4 or INF-Q/LPS on the expression of human neuronal ELAV-like proteins in IMR-32 neuroblastoma line cells. Cytosolic
lysates were isolated from cells treated with IL-4 (10 ng/ml) or INF-Q/LPS (10 ng/ml/1 Wg/ml) for 2 h and were analyzed by immunoblotting
analysis with ANNA-1/anti-Hu antibodies. (b) E¡ect of IL-4 on the expression of human neuronal ELAV-like proteins. Cytosolic lysates were
isolated from cells treated with IL-4 (10 ng/ml) for the times indicated and analyzed by immunoblotting analysis with ANNA-1/anti-Hu anti-
bodies.
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levels. Post-transcriptional control of cytokine expression is
conferred by sequences in the 3P-UTR of its mRNA. In
many instances, the instability of the mRNA has been
mapped to the ARE in the 3P-UTR of TNF-K mRNA.
TNF-K mRNA contains several AREs that can in£uence
mRNA stability. The binding of cytosolic and nuclear pro-
teins to the AREs of the mRNA controls post-transcriptional
regulation and the binding can alter mRNA stability. Several
TNF-K mRNA-binding proteins have been described. Bohja-
nen et al. described how two cytoplasmic proteins, 34 kDa
AU-A and 45 kDa AU-B, in OhdbKMd of the human Jurkat T-
cell line bound to the AU-rich sequence of TNF-K mRNA
[23]. AU-A is ubiquitous in unstimulated cells, while AU-B is
only induced in stimulated T-cells. Hel et al. revealed that at
least six macrophage proteins with apparent molecular masses
of 48, 52, 54, 81, 101, and 150 kDa bind to TNF-K mRNA
[24]. Lewis et al. also described two TNF-K mRNA-binding
proteins in monocyte/macrophage cells [25]. Recently, it was
demonstrated that tritestoraprolin in macrophages binds to
the ARE in the 3P-UTR of TNF-K mRNA, and destabilizes
the mRNA [26]. The present study showed that neuron-spe-
ci¢c proteins also have the capacity to bind to the ARE in the
3P-UTR of TNF-K mRNA.
TNF-K mRNA oligoribonucleotide contains three AUUUA
pentanucleotides and two UUAUUUAUU motifs. Since the
binding of HuC/ple21 to TNF-K mRNA competed with the
class-1 AU-rich sequence of c-myc mRNA, which contains a
single AUUUA, and the formation of the HuC/ple21-TNF-K
mRNA complex competed with the poly(U) homopolymer,
but not with the poly(A) homopolymer, the HuC/ple21 pro-
tein may recognize the clustered uridine stretches in AUUUA,
but may not distinguish clustered AUUUA (class-1 ARE)
from a single AUUUA (class-2 ARE). It has been shown
that neuronal ELAV-like proteins interact with the uridine-
rich sequence in the 3P-UTR of mRNA for granulocyte/mac-
rophage colony stimulating factor (GM-CSF), IL-3, c-fos, c-
myc, p21 waf, Gap-43, and glucose transporter (GLUT1) [27^
31]. These uridine-rich mRNA sequences bind to the ¢rst two
RRMs of the ELAV-like proteins. Our previous studies con-
¢rmed that HuC/ple21 binds to the ARE in the 3P-UTR of IL-
3 and c-myc mRNA, and revealed that the entire ¢rst RRM
and only the octapeptide in the second RRM of HuC/ple21
are necessary and su⁄cient for binding to IL-3 and c-myc
mRNA (Sakai, K. et al., submitted). The present data indicate
that the TNF mRNA-binding region of the HuC/ple21 pro-
tein appears to be identical to IL-3 and c-myc mRNA-binding
regions.
The biological function of HuC/ple21 in TNF-K is not
known. Other ELAV-like proteins play roles in post-transcrip-
tional regulation. Peng et al. demonstrated that elevation of
HuR ubiquitously expressed ELAV-like proteins in the cyto-
plasm, although ectopic overexpression of exogenous HuR
speci¢cally inhibits the c-fos ARE-directed mRNA decay
[32]. The overexpression of Hel-N1, another human neuronal
ELAV-like protein, enhances the cytoplasmic expression of
GLUT1 mRNA [29]. This evidence suggests that HuC/ple21
might play a regulatory role in TNF-K production. INF-Q and
LPS stimulate TNF-K synthesis [11], while IL-4 inhibits it
[19,20]. The mechanism by which IL-4 inhibits LPS-induced
TNF-K production in monocyte/macrophages is still contro-
versial. IL-4 inhibited the accumulation of TNF-K mRNA in
human monocytes by enhancing mRNA degradation [21].
Other reports indicated that IL-4 did not alter TNF-a
mRNA accumulation [33]. In unstimulated macrophages,
TNF-K production was repressed and the AU-rich sequence
in the 3P-UTR of TNF-K mRNA mediated this translational
repression. Mijatovic et al. described how IL-4 induced trans-
lational repression of TNF-K mRNA through the intermedi-
ate ARE in the 3P-UTR of TNF-K mRNA in a macrophage/
monocyte cell line [22]. The present study indicated that in
vitro treatment of IMR-32 cells with IL-4 decreased the ex-
pression of the neuronal ELAV-like proteins. This result sug-
gests the possibility that IL-4 might exert its inhibitory action
on TNF-K mRNA by altering the expression of neuronal
ELAV-like proteins in neurons and neuroblastoma cells. Fur-
ther experiments to examine this possibility are under way.
Analyzing the mechanisms for the interaction between neu-
ronal ELAV-like proteins and TNF-K should be important to
understand the pathophysiological roles of TNF-K in the
brain, and the regulation of neuronal ELAV-like protein ex-
pression may be useful to control the pathological CNS con-
ditions that are related to TNF-K.
References
[1] Selmaj, K.W. and Raine, C.S. (1988) Ann. Neurol. 23, 339^
346.
[2] Probert, L., Akassoglou, K., Pasparakis, M., Kontogeorgos, G.
and Kollias, G. (1995) Proc. Natl. Acad. Sci. USA 92, 11294^
11298.
[3] Talley, A.K., Dewhurst, S., Perry, S.W., Dollard, S.C., Gummu-
luru, S., Fine, S.M., New, D., Epstein, L.G., Gendelman, H.E.
and Gelbard, H.A. (1995) Mol. Cell. Biol. 15, 2359^2366.
[4] New, D.R., Maggirwar, S.B., Epstein, L.G., Dewhurst, S. and
Gelbard, H.A. (1998) J. Biol. Chem. 273, 17852^17858.
[5] Turner, G. (1997) Brain Pathol. 7, 569^582.
[6] Sebire, G., Emilie, D., Wallon, C., Hery, C., Devergne, O., Del-
fraissy, J.F., Galanaud, P. and Tardieu, M. (1993) J. Immunol.
150, 1517^1523.
[7] Cowan, E.P., Alexander, R.K., Daniel, S., Kashanchi, F. and
Brady, J.N. (1997) J. Virol. 71, 6982^6989.
[8] Tchelingerian, J.L., Vignais, L. and Jacque, C. (1994) Neurore-
port 5, 585^588.
[9] Breder, C.D., Tsujimoto, M., Terano, Y., Scott, D.W. and Saper,
C.B. (1993) J. Comp. Neurol. 337, 543^567.
[10] Breder, C.D., Hazuka, C., Ghayur, T., Klug, C., Huginin, M.,
Yasuda, K., Teng, M. and Saper, C.B. (1994) Proc. Natl. Acad.
Sci. USA 91, 11393^11397.
[11] Nitta, T., Ebato, M., Sato, K. and Okumura, K. (1994) Cytokine
6, 171^180.
[12] Sakai, K., Gofuku, M., Kitagawa, Y., Ogasawara, T., Hirose,
G., Yamazaki, M., Koh, C.S., Yanagisawa, N. and Steinman,
L. (1994) Biochem. Biophys. Res. Commun. 199, 1200^1208.
[13] Fried, M. and Crothers, D.M. (1981) Nucleic Acids Res. 9, 6505^
6525.
[14] Riggs, A.D., Suzuki, H. and Bourgeoss, S. (1970) J. Mol. Biol.
48, 67^83.
[15] Hel, Z., Skamene, E. and Radzioch, D. (1996) Mol. Cell. Biol.
16, 5579^5590.
[16] Chung, I.Y. and Benveniste, E.N. (1990) J. Immunol. 144, 2999^
3007.
[17] Burchett, S.K., Weaver, W.M., Westall, J.A., Larsen, A., Kron-
heim, S. and Wilson, C.B. (1988) J. Immunol. 140, 3473^3481.
[18] De Simoni, M.G., Terreni, L., Chiesa, R., Mangiarotti, F. and
Forloni, G.L. (1997) Endocrinology 138, 5220^5226.
[19] Hart, P.H., Vitti, G.F., Burgess, D.R., Whitty, G.A., Piccoli,
D.S. and Hamilton, J.A. (1989) Proc. Natl. Acad. Sci. USA 86,
3803^3807.
[20] te Velde, A.A., Huijbens, R.J., Heije, K., de Vries, J.E. and
Figdor, C.G. (1990) Blood 76, 1392^1397.
[21] Wang, P., Wu, P., Siegel, M.I., Egan, R.W. and Billah, M.M.
(1995) J. Biol. Chem. 270, 9558^9563.
FEBS 21674 5-3-99
K. Sakai et al./FEBS Letters 446 (1999) 157^162 161
[22] Mijatovic, T., Kruys, V., Caput, D., Defrance, P. and Huez, G.
(1997) J. Biol. Chem. 272, 14394^14398.
[23] Bohjanen, P.R., Petryniak, B., June, C.H., Thompson, C.B. and
Lindsten, T. (1992) J. Biol. Chem. 267, 6302^6309.
[24] Hel, Z., Di Marco, S. and Radzioch, D. (1998) Nucleic Acids
Res. 26, 2803^2812.
[25] Lewis, T., Gueydan, C., Huez, G., Toulme, J.J. and Kruys, V.
(1998) J. Biol. Chem. 273, 13781^13786.
[26] Carballo, E., Lai, W.S. and Blackshear, P.J. (1998) Science 281,
1001^1005.
[27] Levine, T.D., Gao, F., King, P.H., Andrews, L.G. and Keene,
J.D. (1993) Mol. Cell. Biol. 13, 3494^3504.
[28] Ma, W.J., Cheng, S., Campbell, C., Wright, A. and Furneaux, H.
(1996) J. Biol. Chem. 271, 8144^8151.
[29] Jain, R.G., Andrews, L.G., McGowan, K.M., Pekala, P.H. and
Keene, J.D. (1997) Mol. Cell. Biol. 17, 954^962.
[30] Chung, S., Eckrich, M., Perrone-Bizzozero, N., Kohn, D.T. and
Furneaux, H. (1997) J. Biol. Chem. 272, 6593^6598.
[31] Joseph, B., Orlian, M. and Furneaux, H. (1998) J. Biol. Chem.
273, 20511^20516.
[32] Peng, S.S., Chen, C.Y., Xu, N. and Shyu, A.B. (1998) EMBO J.
17, 3461^3470.
[33] D’Andrea, A., Ma, X., Aste-Amezaga, M., Paganin, C. and Trin-
chieri, G. (1995) J. Exp. Med. 181, 537^546.
FEBS 21674 5-3-99
K. Sakai et al./FEBS Letters 446 (1999) 157^162162
